NCT07062588
Source recordAI-normalized
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)
This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
AI analysis
Indication: Osteogenesis Imperfecta (OI)
Modality: small molecule
Target: AGA2115, Placebo
Sponsor: Angitia Incorporated Limited
Source URL: ClinicalTrials.gov
Source updated: May 29, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: AGA2115, Placebo
View original source fields
Condition raw: Osteogenesis Imperfecta (OI)
Condition normalized: Osteogenesis Imperfecta (OI)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: AGA2115, Placebo
Target normalized: AGA2115, Placebo